SLC5A2 and stroke disorder: The recently published SCORED trial is the only study to demonstrate a reduction in stroke from SGLT2 inhibition, though that was only identified in a post hoc secondary analysis (HR 0.66, 95% CI 0.48 to 0.91) [7].